The surprise blowup of Protagonist Therapeutics Inc.'s PTG-100 for ulcerative colitis (UC) raised questions not only about the drug but also about the platform from which it emerged, with Stifel analyst Adam Walsh most pointedly interrogating company officials during a conference call to discuss the data.